Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 25, Issue 21, p.3158-67 (2007)


Adult, Antineoplastic Combined Chemotherapy Protocols, Cause of Death, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fever, Follow-Up Studies, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Male, Neoplasms, NEUTROPENIA, Primary Prevention, Randomized Controlled Trials as Topic, Risk Assessment, Survival Analysis, Treatment Outcome


Randomized controlled trials (RCTs) of prophylactic granulocyte colony-stimulating factors (G-CSF) have demonstrated a significant reduction in febrile neutropenia (FN) after systemic chemotherapy. Several RCTs have been published recently that investigate the impact of G-CSF on mortality and relative dose-intensity (RDI).